Encephalitis is a severe infl ammatory disorder of the brain with many possible causes and a complex diff erential diagnosis. Advances in autoimmune encephalitis research in the past 10 years have led to the identifi cation of new syndromes and biomarkers that have transformed the diagnostic approach to these disorders. However, existing criteria for autoimmune encephalitis are too reliant on antibody testing and response to immunotherapy, which might delay the diagnosis. We reviewed the literature and gathered the experience of a team of experts with the aims of developing a practical, syndrome-based diagnostic approach to autoimmune encephalitis and providing guidelines to navigate through the diff erential diagnosis. Because autoantibody test results and response to therapy are not available at disease onset, we based the initial diagnostic approach on neurological assessment and conventional tests that are accessible to most clinicians. Through logical diff erential diagnosis, levels of evidence for autoimmune encephalitis (possible, probable, or defi nite) are achieved, which can lead to prompt immunotherapy.
Introduction
Acute encephalitis is a debilitating neurological disorder that develops as a rapidly progressive encephalopathy (usually in less than 6 weeks) caused by brain infl ammation. 1 The estimated incidence of encephalitis in high-income countries is about 5-10 per 100 000 inhabitants per year; encephalitis aff ects patients of all ages and represents a signifi cant burden to patients, families, and society. 2, 3 Because the most frequently recognised causes of encephalitis are infectious, existing diagnostic criteria and consensus guidelines for encephalitis assume an infectious origin.
1,4-6 However, in the past 10 years an increasing number of non-infectious, mostly autoimmune, encephalitis cases have been identifi ed and some of them do not meet existing criteria. 7 These newly identifi ed forms of autoimmune encephalitis might be associated with antibodies against neuronal cell-surface or synaptic proteins (table) [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] and can develop with core symptoms resembling infectious encephalitis, and also with neurological and psychiatric manifestations without fever or CSF pleocytosis. 7 To improve the recognition of these disorders, in this Position Paper, we aim to provide a practical clinical approach to diagnosis that should be accessible to most physicians.
General scope and objectives
These guidelines focus on autoimmune encephalitis that presents with subacute onset of memory defi cits or altered mental status, accompanied or not by other symptoms and manifestations, with the goal of helping to establish a prompt diagnosis. These guidelines do not address the clinical approach to other CNS autoimmune disorders (stiff person syndrome, 24 progressive encephalomyelitis with rigidity and myoclonus, 25 or autoimmune cerebellopathies 26 ) that usually present with a clinical profi le clearly diff erent from autoimmune encephalitis.
Existing diagnostic criteria for autoimmune encephalitis are too reliant on antibody testing and response to immunotherapy. 27 In our opinion, it is not realistic to include antibody status as part of the early diagnostic criteria in view of the fact that antibody testing is not readily accessible in many institutions and results can take several weeks to obtain. Furthermore, the absence of autoantibodies does not exclude the possibility that a disorder is immune mediated, and a positive test does not always imply an accurate diagnosis. Use of the response to immunotherapy as part of the diagnostic criteria is also not practical because this information is not available at the time of symptom onset or early clinical evaluation. Some patients with autoimmune encephalitis might not respond to immunotherapy or could need intensive and prolonged therapies that are not available in most health-care systems unless a fi rm diagnosis has been pre-established. 28 Conversely, patients with other disorders might respond to immunotherapy (eg, primary CNS lymphoma).
The clinical facts and evidence suggesting that early immunotherapy improves outcome [29] [30] [31] have been considered in the development of the guidelines presented here, in which conventional neurological evaluation and standard diagnostic tests (eg, MRI, CSF, or EEG studies) prevail in the initial assessment. This approach should allow the initiation of preliminary treatment while other studies and comprehensive antibody tests are processed and subsequently used to refi ne the diagnosis and treatment.
The above-mentioned focus of these guidelines and the initial approach based on conventional clinical assessment explain why some disorders are included in the main text and others are included in the appendix or excluded. As an example, we have included acute disseminated encephalomyelitis because the clinical presentation can be similar to that of other autoimmune encephalitis disorders. 32 Another example is Hashimoto's encephalopathy, the existence of which is under discussion, but in practice is frequently listed in the Position Paper diff erential diagnosis of autoimmune encephalitis; 33 thus, we believed it should be discussed, while emphasising the controversies and diagnostic limitations. By contrast, Morvan's syndrome 34 and Rasmussen's encephalitis, 35 which have a solid autoimmune basis, are not included in the main text because they usually follow a more chronic course and the initial or predominant symptoms (peripheral nerve hyperexcitability, or focal seizures and unilateral defi cits) are diff erent from those mentioned above. We recognise the overlap that can occur between these disorders and autoimmune encephalitis and for this reason they are discussed in the appendix. Because children do not develop many of the autoimmune encephalitis disorders that aff ect adults, and the syndrome presentation might be diff erent or less clinically recognisable, these guidelines should be applied with caution in children, particularly in children younger than 5 years.
36,37

Methods
An initial draft of these guidelines was developed by two authors (FG and JD) and subsequently underwent three rounds of reviews and updates by a panel of investigators who have expertise in autoimmune encephalitis. In the fi rst stage, we reviewed previously published guidelines and diagnostic criteria for encephalitis (of any cause or idiopathic). This review along with clinical experience with forms of autoimmune encephalitis described in the past 10 years (eg, some of them not necessarily causing alteration in consciousness, but changes in memory or personality) led us to a defi nition of so-called possible autoimmune encephalitis, which is not dependent on neuronal autoantibody status. We next reviewed the existing criteria for specifi c clinical syndromes (eg, limbic encephalitis or Bickerstaff 's brainstem encephalitis), identifi ed other disorders for which criteria were unclear, and modifi ed or developed new diagnostic criteria (eg, probable anti-NMDA receptor encephalitis), which focused on symptom assessment and standard paraclinical tests, and were not dependent on autoantibody status. This work resulted in the establishment of three levels of clinical evidence for autoimmune encephalitis: possible and probable for which the autoantibody status is not needed in most cases, and defi nite for which the autoantibody status is often needed. In parallel, we reviewed the literature and our experience in neuronal autoantibody studies and identifi ed caveats for interpretation, which led to recommendations for the use and interpretation of fi ndings of autoantibodies in autoimmune encephalitis.
Initial clinical assessment: possible autoimmune encephalitis
We regard a patient with new-onset encephalitis as having possible autoimmune encephalitis if the criteria shown in panel 1 are met. These criteria diff er from those previously proposed for encephalitis (any cause or idiopathic) in which changes in the level of consciousness, fever, CSF pleocytosis, and EEG alterations are more often needed.
1,4-6 These criteria needed to be adapted for autoimmune encephalitis because patients with autoimmune encephalitis could present with memory or behavioural defi cits without fever or alteration in the level of consciousness, or with normal brain MRI or CSF results. 7 In this context, memory defi cits refer to the inability to form new, long-term memories owing to hippocampal dysfunction, or problems with working memory, which refers to structures and processes used for temporary storage and manipulation of information.
Most patients with encephalitis undergo brain MRI at early stages of the disease. The fi ndings could be normal or non-specifi c, but sometimes they might suggest an LGI1=leucine-rich glioma inactivated 1. CASPR2=contactin associated protein 2. DPPX=dipeptidyl-peptidase-like protein-6. MOG=myelin oligodendrocyte glycoprotein. *Amphiphysin or CV2 (CRMP5) antibodies instead of Hu antibodies in a few patients with limbic encephalitis and small-cell lung carcinoma. †Limbic encephalitis frequently associated with hypothalamic and mesencephalic involvement. ‡GAD antibodies occur more frequently in patients with stiff person syndrome and cerebellar ataxia. The association with cancer preferentially occurs in patients with limbic encephalitis. §Tumours found more frequently in men older than 50 years. 23 ¶Ovarian teratoma usually found in young women aged 12-45 years. ||Morvan's syndrome usually has a more chronic clinical course, but might present with predominant cognitive and behavioural symptoms fulfi lling criteria of possible autoimmune encephalitis. **Thymoma associated with Morvan's syndrome rather than limbic encephalitis. † †Encephalitis associated with diarrhoea and hyperekplexia. ‡ ‡Mostly restricted to children.
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autoimmune cause (see below). By contrast, alterations in EEG are rarely specifi c. We acknowledge the use of some EEG patterns in the diagnosis of specifi c forms of encephalitis (eg, extreme delta brush in anti-NMDA receptor encephalitis), 38 in the diff erential diagnosis of other disorders (Creutzfeldt-Jakob disease), or to reveal subclinical seizures and non-convulsive status epilepticus.
In addition to the above criteria, patients should be carefully examined for other diseases that can mimic autoimmune encephalitis and cause rapidly progressive encephalopathy (appendix). These diseases should be excluded before immunotherapy begins and in most instances a detailed clinical history, complete general and neurological examination, routine blood and CSF analysis, and brain MRI including diff usion sequences will suffi ce to accomplish this goal. The most frequent diff erential diagnoses are herpes simplex virus encephalitis and other CNS infections. Importantly, CSF herpes simplex virus PCR can be negative if done too early (eg, within 24 h), and this test should be repeated if the clinical suspicion remains high. 39 Previous reviews have addressed the diff erential diagnosis of infectious encephalitis.
1,40
Approach to patients with clinically recognisable syndromes
A substantial number of patients with autoimmune encephalitis do not present with a well defi ned syndrome. In some of these patients, demographic information and some comorbidities (eg, diarrhoea, ovarian teratoma, faciobrachial dystonic seizures) might initially suggest the underlying disorder (anti-dipeptidyl-peptidase-like protein-6 [DPPX], anti-NMDA receptor, anti-leucine-rich, glioma-inactivated 1 [LGI1] encephalitis), but these features are not pathognomonic and might be absent in some patients. 11, 41, 42 In such cases, the diagnosis of defi nite autoimmune encephalitis greatly depends on the results of autoantibody tests. By contrast, disorders exist in which the clinical syndrome and MRI fi ndings allow for classifi cation as probable or defi nite autoimmune encephalitis before the autoantibody status is known. These include limbic encephalitis, acute disseminated encephalomyelitis and other syndromes with MRI features that predominantly involve white matter, anti-NMDA receptor encephalitis, and Bickerstaff 's brainstem encephalitis (fi gure 1).
43
Autoimmune limbic encephalitis
Diagnostic criteria for autoimmune limbic encephalitis are shown in panel 2. 44, 45 We have modifi ed our previous criteria to include evidence of bilateral involvement of the medial temporal lobes on T2-weighted fl uidattenuated inversion recovery (FLAIR) MRI studies (fi gure 2; see below). 46, 47 In our proposed criteria, antibody status is not needed to consider limbic encephalitis as having a defi nite autoimmune origin because immunemediated limbic encephalitis can occur without detectable autoantibodies (fi gure 2, appendix). 48, 49 Measurement of autoantibodies, however, remains important for two reasons: their presence clarifi es the immunological subgroup of limbic encephalitis, with comorbidities, tumour association, and prognosis that might diff er according to the autoantibody; 8, 10, [50] [51] [52] [53] and, in patients who do not satisfy the indicated criteria, detection of autoantibodies establishes the diagnosis of autoimmune limbic encephalitis (panel 2).
The clinical picture of limbic encephalitis is characterised by rapid development of confusion, working memory defi cit, mood changes, and often seizures. The subacute development of short-term memory loss is considered the hallmark of the disorder, but it can be overlooked because of the presence of other symptoms. 46 CSF analysis shows mild-to-moderate lymphocytic pleocytosis (usually less than 100 white blood cells per mm³) in 60-80% of patients, and elevated IgG index or oligoclonal bands in approximately 50% of cases. 46, 51, 52 Among all immunological subtypes of limbic encephalitis, patients with LGI1 antibodies present with a lower frequency of CSF pleocytosis (41%) or elevated CSF protein concentrations (47%) and rarely have intrathecal IgG synthesis. 54 The absence of infl ammatory changes in the CSF of these patients might initially suggest a non-infl ammatory encephalopathy.
MRI often shows increased signal on T2-weighted FLAIR imaging in the medial aspect of the temporal lobes. Although limbic encephalitis can occur with MRI evidence of unilateral involvement (or be normal) we do not consider these cases as defi nite limbic encephalitis unless specifi c antibodies are subsequently detected. The reason for this is that several non-immune disorders could result in similar unilateral MRI abnormalities, including among 1 Subacute onset (rapid progression of less than 3 months) of working memory defi cits (short-term memory loss), altered mental status*, or psychiatric symptoms 2 At least one of the following:
• New focal CNS fi ndings • Seizures not explained by a previously known seizure disorder • CSF pleocytosis (white blood cell count of more than fi ve cells per mm³) • MRI features suggestive of encephalitis † 3 Reasonable exclusion of alternative causes (appendix) *Altered mental status defi ned as decreased or altered level of consciousness, lethargy, or personality change. †Brain MRI hyperintense signal on T2-weighted fl uid-attenuated inversion recovery sequences highly restricted to one or both medial temporal lobes (limbic encephalitis), or in multifocal areas involving grey matter, white matter, or both compatible with demyelination or infl ammation.
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Fulfil criteria for antibodynegative AE?
(panel 7)
Thyroid Abs? 43 or positive GQ1b antibodies if core symptoms are incomplete.
others, seizures, herpes simplex virus encephalitis, or gliomas (appendix, fi gure 2). 40, [55] [56] [57] MRI fi ndings of immune-compromised patients with human herpes virus 6-associated encephalitis can mimic precisely fi ndings from patients with autoimmune limbic encephalitis, but the clinical setting is diff erent and directs the diagnosis. 58 By contrast, the fi ndings in herpes simplex virus encephalitis are less confi ned to the limbic system, can occur with haemorrhagic features, and often show restricted diff usion abnormalities and contrast uptake. 59 Some demographic and clinical clues could suggest the underlying immune response of limbic encephalitis (appendix), but the immunological subtypes can be established only by measurement of autoantibodies. 7 Distinction among immunological subtypes is important because those associated with onconeuronal antibodies are much less responsive to immunotherapy than those associated with cell-surface antibodies. The onconeuronal antibodies that more frequently occur with limbic encephalitis are Hu and Ma2, and patients who have these antibodies almost always have an underlying cancer. 8, 9 By contrast, the neuronal cellsurface antibodies that are more frequently associated with limbic encephalitis are LGI1, 18 GABA B receptor, 51, 60 and AMPA receptor 52 antibodies (see appendix for less frequent antibodies). The frequency and type of tumours vary according to the antibody (table). 7 Antibodies against the intracellular antigen glutamic acid decarboxylase (GAD) occur in a subgroup of patients with limbic encephalitis. These patients are mainly young women (median age 23 years) with predominant seizures and no evidence of cancer. 10 The risk of cancer, usually small-cell lung carcinoma or thymoma, is higher, however, among patients with GAD antibodies and limbic encephalitis who are older than 50 years or have concomitant GABA B receptor antibodies. 23 
Acute disseminated encephalomyelitis and other syndromes with MRI features of demyelination
Acute disseminated encephalomyelitis is a monophasic, infl ammatory disease of the CNS that mainly occurs in children and adults younger than 40 years. 61 The disorder can be preceded by an acute systemic infection or vaccination. 62, 63 It is characterised by a variable extent of encephalopathy (a mandatory criterion for a defi nitive diagnosis; panel 3), and other neurological signs, such as cranial nerve palsies, ataxia, hemiparesis, myelopathy, or optic neuritis. CSF analysis typically shows mild pleocytosis (less than 50 lymphocytes per mm³), but CSF oligoclonal bands are uncommon (less than 7% of all cases). 64 Brain MRI shows multiple, large (>2 cm) abnormalities on T2-weighted FLAIR imaging that can be present in the supratentorial white matter, basal ganglia, brainstem, cerebellum, and spinal cord, with or without contrast enhancement (fi gure 2). 65 There are no specifi c biomarkers of acute disseminated encephalomyelitis, and a set of criteria has been proposed for children (panel 3). 32 According to these criteria one of the requirements for defi nite acute disseminated encephalomyelitis is the absence of new clinical and MRI fi ndings 3 months after symptom onset. Except for this criterion (which cannot be predicted at onset), we believe the rest of the criteria are robust enough to establish that patients who meet them have probable acute disseminated encephalomyelitis and can be started on immunotherapy. 1 Subacute onset (rapid progression of less than 3 months) of working memory defi cits, seizures, or psychiatric symptoms suggesting involvement of the limbic system 2 Bilateral brain abnormalities on T2-weighted fl uid-attenuated inversion recovery MRI highly restricted to the medial temporal lobes † 3 At least one of the following:
• CSF pleocytosis (white blood cell count of more than fi ve cells per mm 3 ) • EEG with epileptic or slow-wave activity involving the temporal lobes 4 Reasonable exclusion of alternative causes (appendix) *If one of the fi rst three criteria is not met, a diagnosis of defi nite limbic encephalitis can be made only with the detection of antibodies against cell-surface, synaptic, or onconeural proteins. †¹⁸Fluorodeoxyglucose (¹⁸F-FDG) PET can be used to fulfi l this criterion. Results from studies from the past 5 years suggest that ¹⁸F-FDG-PET imaging might be more sensitive than MRI to show an increase in FDG uptake in normal-appearing medial temporal lobes. 44, 45 
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Evidence exists that myelin oligodendrocyte glycoprotein (MOG) antibodies can transiently occur in almost 50% of children with acute disseminated encephalomyelitis. 20, 66, 67 At present, the inclusion of MOG antibodies in the diagnostic criteria for acute disseminated encephalomyelitis is not considered for two reasons: the antibodies can be present in demyelinating disorders with encephalopathy, but without MRI features of acute disseminated encephalomyelitis, or in patients with demyelinating disorders without encephalopathy; 68 and antibody testing remains unavailable at many centres.
Susac's syndrome is a rare, but important, diff erential diagnosis in patients who meet criteria for possible autoimmune encephalitis and have MRI features of demyelination. The syndrome is considered an autoimmune vasculopathy resulting in microvessel thromboses at three levels: the brain, retina, and inner ear. 69 In a review of 304 cases of Susac's syndrome, 230 (76%) patients presented with encephalopathy, but simultaneous involvement of the three levels at disease onset occurred in only 31 of 247 (13%) patients. 70 The diagnosis is based on presence of branch retinal artery occlusions on fl uorescein angiography, and MRI fi ndings including snowball-like lesions or holes in the central portion of the corpus callosum and other periventricular white matter abnormalities on T2-weighted FLAIR imaging (fi gure 2). These MRI fi ndings are diff erent from those seen in acute disseminated encephalomyelitis and in the setting of encephalopathy are highly suggestive of Susac's syndrome. 
Anti-NMDA receptor encephalitis
Anti-NMDA receptor encephalitis is frequently recognisable on clinical grounds and is associated with CSF IgG antibodies against the GluN1 subunit of the NMDA receptor.
11 These antibodies are highly specifi c and their pathogenicity has been demonstrated in cultured neurons and in-vivo models. 71, 72 In a multicentre, observational study of 577 patients, the disease was shown to predominantly aff ect young individuals (549 [95%] younger than 45 years, and 211 [37%] younger than 18 years) with a female sex predominance of 4:1. This female predominance was less evident in children younger than 12 years and adults older than 45 years. 28 The frequency of an underlying tumour varied with age and sex, ranging from 0-5% in children (male and female) younger than 12 years, to 58% in women older than 18 years (usually an ovarian teratoma). 28 Adults older than 45 years have a lower frequency of tumours (23%), and these are usually carcinomas instead of teratomas.
11
Teenagers and adults usually present with abnormal behaviour (psychosis, delusions, hallucinations, agitation, aggression, or catatonia) with irritability and insomnia, followed by speech dysfunction, dyskinesias, memory defi cits, autonomic instability, and a decrease in the level of consciousness. 11, 73 Seizures can take place at any time during the disease, but tend to occur earlier in males. 74 In the above-mentioned observational cohort study, 28 compared with teenagers and adults, young children more frequently presented with abnormal movements or seizures. Regardless of the patient's age and presentation, the clinical picture at 3-4 weeks after symptom onset was similar in most cases. By the end of the fi rst month, 498 (87%) of 571 patients had four or more of the following categories of symptoms, including (from highest-to-lowest frequency) abnormal behaviour and cognition; memory defi cit; speech disorder; seizures; abnormal movements (orofacial, limb, or trunk dyskinesias); loss of consciousness or autonomic dysfunction; central hypoventilation; and cerebellar ataxia or hemiparesis. 28 Only six patients (1%) had one category of symptoms.
On the basis of these data, and while waiting for confi rmatory IgG anti-GluN1 antibody results, we regard a patient with rapidly progressive encephalopathy as having probable anti-NMDA receptor encephalitis if they satisfy the criteria shown in panel 4. Memory defi cit is common, but we have excluded it from the criteria because it is diffi cult to assess in patients with psychosis or agitation, or in young children. Hemiparesis and cerebellar ataxia are not included because these symptoms are less frequent and if they occur they predominantly aff ect children in combination with the other symptoms. In patients who meet these criteria, immunotherapy and the search for a neoplasm (according to sex and age) should be started. In a retrospective analysis of data from the observational cohort study, 28 425 (80%) of 532 patients with anti-NMDA receptor encephalitis met these criteria within the fi rst month of symptom onset, including 254 (74%) of 342 without teratoma and 171 (90%) of 189 with teratoma.
Patients with partial symptoms who might be missed with these initial criteria will be identifi ed with an antibody test (fi gure 1). Antibody studies should include CSF analysis; a risk of false-negative or false-positive diagnoses 
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exists if only serum is used. 75 Findings from three other studies have suggested that serum testing is less consistent, or showed antibodies in patients without anti-NMDA receptor encephalitis or immune-mediated disorders. 74, 76, 77 Analysis of CSF for the presence of NMDA receptor antibodies is mandatory in patients with relapsing symptoms after herpes simplex encephalitis. 78, 79 This relapsing form of herpes simplex encephalitis is an autoimmune disorder that at times is indistinguishable from the full-blown syndrome of anti-NMDA receptor encephalitis, aff ects 20% of patients with herpes simplex encephalitis, and manifests with new-onset choreoathetosis (predominantly in children) 79, 80 or psychiatric symptoms (mainly in adults and teenagers) a few weeks or, rarely, months after the viral infection. 81 In addition to NMDA receptor antibodies, a few patients develop GABA A receptor or dopamine receptor 2 antibodies.
81,82
Bickerstaff 's brainstem encephalitis
Bickerstaff 's brainstem encephalitis is characterised by subacute onset, in less than 4 weeks, of progressive impairment of consciousness along with ataxia and bilateral, mostly symmetrical, ophthalmoparesis. 83 The syndrome is usually preceded by an infectious event, runs a monophasic course, and has a good outcome. Additionally, patients frequently develop pupillary abnormalities, bilateral facial palsy, Babinski's sign, and bulbar palsy. Generalised limb weakness can occur, which overlaps with features of Guillain-Barré syndrome. 84 CSF pleocytosis occurs in 45% of patients. Brain MRI is usually normal, but brainstem abnormalities on T2-weighted FLAIR imaging are present in 23% of patients. 83 Most of the proposed criteria for Bickerstaff 's brainstem encephalitis include the triad of abnormal mental status, bilateral external ophthalmoplegia, and ataxia (panel 5). 83 IgG anti-GQ1b antibodies are highly specifi c for this disorder and the related Miller-Fisher syndrome, leading some clinicians to group these disorders under the term GQ1b antibody syndrome. 22 We agree with the criteria proposed in 2014, which do not specify the need for GQ1b antibody testing for a defi nitive diagnosis of Bickerstaff 's brainstem encephalitis because up to 32% of patients do not have detectable antibodies. 43 Measurement of these antibodies, however, allows confi rmation of the diagnosis in patients with incomplete syndromes or atypical symptoms, or when the altered mental status prevents the assessment of ataxia. The occasional complexity in the diff erential diagnosis is exemplifi ed by the third case in the original report by Bickerstaff and Cloake, 85 in which a 24-year-old woman, who was admitted for ovarian cystectomy, in addition to brainstem symptoms, developed seizures, hyperthermia, psychosis, and episodes of maniacal excitement alternating with catatonia that lasted 2 months. Measurement of GQ1b and NMDA receptor antibodies (not available at that time) would probably have clarifi ed the diagnosis.
Disorders to consider in the diff erential diagnosis of Bickerstaff 's brainstem encephalitis include Listeria rhombencephalitis, EV71 encephalitis in children, paraneoplastic and postinfectious brainstem encephalitis, chronic lymphocytic infl ammation with pontine perivascular enhancement responsive to steroids (CLIPPERS), neurosarcoidosis, and primary CNS lymphoma.
86-88
Antibody testing: clinical considerations and caveats
The detection of specifi c autoantibodies (table, fi gure 1) establishes a defi nitive diagnosis of autoimmune encephalitis, identifi es immunological subtypes of limbic encephalitis, and assists in the diff erential diagnosis of atypical clinical cases. Therefore, measurement of antibodies is a crucial step in the defi nite diagnosis of many types of autoimmune encephalitis and clinicians must be aware of potential pitfalls in the interpretation of results.
Several concepts that apply to classic onconeuronal or GAD antibodies (discussed later) are not applicable to antibodies against neuronal cell-surface proteins. Onconeuronal and GAD antibodies target intracellular proteins and because they are present in the serum and CSF, and their epitopes are linear, they are detectable with many techniques including ELISA, immunoblotting, and immunohistochemistry. By contrast, antibodies 
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against neuronal cell-surface proteins have diff erent properties that should be considered for a better understanding of the most appropriate tests to use and interpretation of their results. Here, we discuss these issues and some more general caveats applicable to the detection of autoantibodies.
Conformational antigens
Most antibodies against neuronal cell-surface proteins recognise target epitopes only if they are expressed in their native conformation. Techniques that meet this requirement are cell-based assays (used by most clinical laboratories), immunohistochemistry of brain sections adapted to membrane proteins (commercially available; sometimes used as a confi rmatory test), and immunocytochemistry of cultures of dissociated rodent live hippocampal neurons (only used in research laboratories).
12
Molecular precision
The target antigens of autoantibodies can be composed of several subunits. Antibodies against each of the subunits can have diff erent clinical signifi cance and implications. For example, the NMDA receptor is a heterotetramer comprised of two GluN1 subunits and two GluN2/3 subunits. Detection of IgG antibodies against the GluN1 subunit is a signature of anti-NMDA receptor encephalitis. 89 By contrast, antibodies against linear epitopes of GluN2 or GluR ε2 have been reported in many diff erent disorders and their clinical signifi cance is uncertain. 90 Molecular precision is important for the voltage-gated potassium channel complex (VGKC) antibodies. This name was adopted by some investigators after they showed that the target antigen was not the VGKC itself, but the proteins LGI1 and contactin-associated proteinlike 2 (CASPR2), complexed with the VGKC. 17, 18 Antibodies against LGI1 and CASPR2 have well defi ned syndrome associations. By contrast, radioimmunoassay studies have shown that antibodies directed against the VGKC complex that do not target LGI1 or CASPR2 are not syndrome specifi c and cannot be used as proof of an immune-mediated pathogenesis.
91-93
Immunoglobulin class
The antibodies associated with autoimmune encephalitis in the table are IgG antibodies. Detection of IgA or IgM antibodies against any of these antigens has unclear signifi cance. For example, whereas IgG antibodies against the GluN1 subunit of the NMDA receptor are specifi c for anti-NMDA receptor encephalitis, IgM or IgA antibodies have been reported in the serum of 10% of patients with diff erent disorders and in a similar proportion of healthy people.
94
CSF studies
Analysis of CSF plays a central part in all diagnostic criteria for encephalitis, including infectious encephalitis, and has a similar role in the detection of autoantibodies in suspected cases of autoimmune encephalitis. The investigation of CSF antibodies is important for four reasons: (1) most patients with autoimmune encephalitis have CSF antibodies and relevant antibodies might be found only in the CSF 51,52 -eg, in patients with anti-NMDA receptor encephalitis up to 14% have antibodies in the CSF, but not in the serum; 75 (2) the repertoire of antibodies in the CSF and serum can be diff erent in the same patient (eg, NMDA receptor in CSF and serum, and GABA A receptor only in serum), and in this setting, the types of antibodies in the CSF usually determine the clinical picture; 14 (3) for some disorders, such as anti-NMDA receptor encephalitis, the concentration of CSF antibodies correlates better with the clinical course than antibody concentrations in the serum; 75 and (4) neuronal antibody testing using serum and cell-based assays could lead to false-positive or false-negative results; this problem rarely occurs with CSF analysis. On the basis of these data and while we await larger studies with other autoantibodies, our recommendation is to include both CSF and serum for neuronal antibody testing in patients with suspected autoimmune encephalitis.
These concepts have implications for patient management. The approach of fi rst testing the serum and proceeding with the CSF if negative could delay diagnosis. If serum testing is positive, but the CSF is negative, or if the clinical picture does not fi t with the antibody identifi ed, the possibilities of a laboratory result unrelated to the syndrome or a false-positive result should be considered; 95 in such cases, the laboratory should be contacted regarding retesting of the samples or the use of confi rmatory tests (eg, brain immunohistochemistry or cultured neurons). Finally, treatment decisions during the course of the disease 
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should rely more on clinical assessment than on antibody titres. Although the titres might correlate with the clinical course, this correlation is imperfect, and antibodies often remain detectable after clinical recovery.
75
Antibodies in demyelinating disorders that overlap with anti-NMDA receptor encephalitis About 4% of patients with anti-NMDA receptor encephalitis develop two diff erent syndromes that can occur separately or simultaneously. Each syndrome is related to a distinct pathogenic mechanism, such as anti-NMDA receptor encephalitis along with MOG-related or aquaporin 4 (AQP4)-related syndromes (fi gure 2). 96 In practice, physicians should be aware that a demyelinating disorder can present as an autoimmune encephalitis disorder, and that overlapping syndromes can occur. Patients with a demyelinating disorder and atypical features (eg, dyskinesias or prominent psychiatric manifestations) or patients with anti-NMDA receptor encephalitis with atypical features (eg, optic neuritis or demyelination on MRI) should be comprehensively studied for coexisting disorders, rather than being classifi ed as having an expansion of the spectrum of a single disease. These clinical situations imply the need for testing for AQP4 and MOG antibodies in the serum (because intrathecal production of these antibodies is rare), 20, 97 and for NMDA receptor antibodies in the serum and CSF.
GAD antibodies in limbic encephalitis and other syndromes
Serum antibodies against intracellular GAD can occur at low titres in 1% of healthy people and in 80% of people with type 1 diabetes mellitus. 98 Only serum GAD antibodies at high titres are associated with autoimmune neurological disorders, such as limbic encephalitis and other syndromes. 99 The defi nition of high titre depends on the technique used, but neurological symptoms usually occur with titres that are 100-1000 times higher than those seen in people with diabetes. When examining a patient with limbic encephalitis, clinicians should keep in mind that, albeit rare, high titres of serum GAD antibodies could suggest the presence of diabetes or other endocrine disorders. In this setting, specifi c intrathecal production of GAD antibodies or CSF oligoclonal bands support an association with the neurological syndrome.
99
Approach to patients without recognisable syndromes or autoantibodies
After excluding all well characterised syndromes of autoimmune encephalitis (with or without autoantibodies) and other syndromes accompanied by well defi ned autoantibodies, a group of patients who have possible autoimmune encephalitis will remain (panel 1). Patients in this group can be regarded as having probable autoimmune encephalitis if they satisfy criteria for Hashimoto's encephalopathy (panel 6) 101 or the criteria proposed in panel 7.
The defi nition of Hashimoto's encephalopathy has been linked to a good response to steroids, and consequently the disorder is deemed immune mediated, despite the unclear physiopathology and the absence of response to prednisone in the patient in the original report. 103 This disorder predominantly aff ects women in a wide age range, from the fi rst to the eighth decade of life. Overt or subclinical thyroid disease, usually hypothyroidism, occurs in most cases (54 of 80 patients in a review of reported cases). 104 By defi nition, patients develop encephalopathy, which can be associated with seizures (56 of 85 reviewed patients), myoclonus Position Paper (32 patients) , hallucinations (31 patients), and stroke-like episodes (23 patients) with normal or non-specifi c CSF and brain MRI abnormalities. 33, 104 Most reported patients (66 of 69 patients treated with corticosteroids with or without levothyroxine) improved; 104 however, this outcome is expected in view of the defi nition of the disorder, which in 2006 was renamed as steroid-responsive encephalopathy with autoimmune thyroiditis. 101 Patients who have a non-specifi c encephalopathy with subclinical or overt thyroid disease, anti-thyroid antibodies, and no better explanation for the symptoms should be considered for a trial of steroids. However, thyroid antibodies are not specifi c for Hashimoto's encephalopathy because they are present in up to 13% of healthy individuals (27% in white women older than 60 years) and patients with other autoimmune encephalitis disorders. 100 Similarly, α-enolase antibodies have been identifi ed in up to 68% of patients with Hashimoto's encephalopathy, 105 but they cannot be used as biomarkers of the disease because they have been detected in healthy people and in patients with other autoimmune disorders. 33, 106 We propose use of the term Hashimoto's encephalopathy only when rigorous clinical assessment and comprehensive testing for well characterised neuronal antibodies exclude other potential causes of encephalopathy (panel 6). 100 Because the underlying pathogenic mechanism is unclear, diagnosis of Hashimoto's encephalopathy should be classifi ed as probable autoimmune encephalitis (fi gure 1).
Other poorly defi ned syndromes with no antibodies can be regarded as probable autoimmune encephalitis if they satisfy the criteria in panel 7. When considering these criteria the following should be kept in mind:
(1) the absence of pleocytosis does not rule out autoimmune encephalitis (eg, 59% of patients with LGI1 antibody-associated encephalitis do not have CSF pleocytosis), 54 normal routine CSF studies do not imply that there is no intrathecal IgG synthesis or an absence of CSF antibodies, and in fact, almost all antibodyassociated autoimmune encephalitis disorders have detectable antibodies in the CSF; (2) autoimmune encephalitis can occur with normal or atypical MRI fi ndings (fi gure 2); and (3) mainly applicable to children, several genetic disorders, mitochondrial diseases, or leukodystrophies can develop with MRI and CSF abnormalities (eg, symmetric brain involvement, pleocytosis) similar to those found in autoimmune encephalitis and might also respond to steroids. 102 For patients who meet the criteria of probable autoimmune encephalitis, but do not have well characterised autoantibodies (panel 7), investigation of CSF and serum for new antibodies in reference laboratories is important. Detection of CSF antibodies that react with the cell surface of neurons (even when the antigens are unknown) strongly supports the diagnosis of autoimmune encephalitis; the clinical signifi cance of the detection of antibodies in serum only is less clear (eg, serum GABA A receptor antibodies are associated with a wide variety of symptoms, some of unclear clinical relevance). 14, 107 The importance of these studies cannot be overemphasised and surpasses the clinical signifi cance of infl ammatory infi ltrates in a brain biopsy, which suggest an infl ammatory process, but cannot be used to establish the autoimmune cause.
For patients who do not satisfy criteria for probable autoimmune encephalitis and do not have any autoantibody (well characterised or against unknown neuronal cell-surface antigens), or who do not satisfy criteria for any of the aforementioned diseases and syndromes, the likelihood of an autoimmune cause becomes smaller and alternative diagnoses should be reconsidered.
There are several autoimmune CNS disorders (primary CNS angiitis [appendix], 108 Rasmussen's encephalitis, 35 Morvan's syndrome 34 ) and other diseases of unclear cause (eg, febrile infection-related epilepsy syndrome [FIRES] 
109
) that are often considered in the diff erential diagnosis of autoimmune encephalitis (panel 1). We have summarised these disorders (appendix) and emphasised the clinical features that lead to the diff erential diagnosis with autoimmune encephalitis.
Implications and directions for future research
We have shown that it is possible to proceed through a logical diff erential diagnosis of autoimmune encephalitis using criteria based on conventional clinical neurological assessment and standard diagnostic tests (MRI, EEG, and CSF studies). Through this approach, levels of evidence of probable and defi nite autoimmune encephalitis can be achieved early and therapies implemented quickly, with the possibility of fi ne-tuning the diagnosis and treatment when antibody results become available. Treatment recommendations for each type of autoimmune encephalitis are outside the scope of these guidelines; moreover, the evidence is limited for many of these disorders. The stepwise escalation of immunotherapy, which includes fi rst-line therapy (steroids; IVIg, plasma exchange, or both) followed, if there is no clinical response, by second-line therapy (rituximab, cyclo phosphamide, or other), is often used in the treatment of anti-NMDA receptor and other autoimmune types of encephalitis, but rituximab is increasingly being considered as a fi rst-line therapy. 16 Not all autoimmune encephalitis syndromes, however, need a similar approach. For example, patients with limbic encephalitis and LGI1 antibodies appear to respond faster and better to steroids than patients with anti-NMDA receptor encephalitis, yet the long-term outcome seems to be better for those with anti-NMDA receptor encephalitis. 28, 53 We acknowledge the need for future research to drive improvements in the diagnosis of autoimmune encephalitis. The repertoire of autoimmune encephalitis Position Paper in children is diff erent from that of adults. The younger the child the more diffi cult it is to recognise specifi c autoimmune encephalitis syndromes, which suggests that guidelines for paediatric autoimmune encephalitis will be more dependent on antibody and other ancillary tests than the syndrome-based guidelines in this Position Paper. Conversely, clinical assessment of autoimmune encephalitis in elderly people (aged over 65 years) has another set of challenges imposed by the high frequency of brain changes in this group caused by systemic and non-immune-mediated disorders, or the coexistence of age-related disorders that can aff ect memory and cognition. Other areas of improvement will be dictated by cumulative clinical experience, better diff erential diagnoses with diseases that resemble autoimmune encephalitis, and increased accessibility to antibody tests with faster turnaround, while keeping in mind the caveats for interpretation of some of these tests.
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